avikdutta1988Aug 19, 20211 min readPalbociclib/Ruxolitinib Combo Shows Preclinical Promise in Myelofibrosishttps://www.onclive.com/view/palbociclib-ruxolitinib-combo-shows-preclinical-promise-in-myelofibrosis
https://www.onclive.com/view/palbociclib-ruxolitinib-combo-shows-preclinical-promise-in-myelofibrosis
Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654Published: Jun. 8, 2022 at 8:00 AM EDT CAMBRIDGE, Mass., June 8, 2022 /PRNewswire/ -- Sumitomo Pharma Oncology, Inc., a clinical-stage...
UVA DISCOVERY SUGGESTS POTENTIAL NEW TREATMENT FOR DEADLY BLOOD CANCERhttps://news.virginia.edu/content/uva-discovery-suggests-potential-new-treatment-deadly-blood-cancer A drug used to treat certain...
Comentarios